Related Experiment Videos
Antisense therapy of influenza
1Department of Industrial Chemistry, Chiba Institute of Technology, 2-17-1 Tsudanuma, Narashino, 275-0016, Chiba, Japan.
Summary
Liposomally encapsulated antisense phosphorothioate oligonucleotides (S-ODNs) targeting PB2-AUG demonstrated significant in vitro and in vivo antiviral activity against influenza A virus. This novel delivery method shows promise for treating respiratory infections.
Area of Science:
- Virology
- Oligonucleotide Therapeutics
- Drug Delivery Systems
Background:
- Influenza A virus poses a significant threat, necessitating novel therapeutic strategies.
- Antisense phosphorothioate oligonucleotides (S-ODNs) offer potential antiviral activity.
- Liposomal encapsulation can enhance oligonucleotide delivery and efficacy.
Purpose of the Study:
- To evaluate the antiviral efficacy of liposomally encapsulated S-ODNs against influenza A virus.
- To compare the activity of S-ODNs targeting different viral sites (PB1, PB2, PA, NP).
- To assess the in vivo therapeutic potential of promising S-ODN candidates in a mouse model.
Main Methods:
- MTT assay using MDCK cells to determine inhibition of virus-induced cytopathogenic effects.
- Testing of free and liposomally encapsulated S-ODNs targeting four influenza A virus sites.
- In vivo study using Balb/c mice infected with influenza A virus (A/PR/8/34) and treated intravenously with liposomally encapsulated S-ODNs.
Main Results:
- Liposomally encapsulated S-ODN targeting the PB2-AUG initiation codon showed high inhibitory effects in vitro.
- Encapsulated S-ODNs exhibited greater activity than free S-ODNs, with sequence-specific inhibition.
- Intravenous administration of liposomally encapsulated PB2-AUG significantly increased survival rates and prolonged mean survival time in a dose-dependent manner in infected mice.
Conclusions:
- Liposomal encapsulation enhances the antiviral activity of S-ODNs against influenza A virus.
- S-ODN targeting PB2-AUG demonstrates potent in vivo antiviral efficacy in a mouse model.
- This study presents the first successful demonstration of in vivo antiviral activity of systemically administered antisense oligonucleotides for experimental influenza A virus respiratory infections.